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Abstract
The number of kidney podocytes is reduced in diabetic nephropathy. Advanced glycation end products (AGEs) accumulate
in patients with diabetes and promote the apoptosis of podocyte by activating the forkhead box O4 (Foxo4) transcription
factor to increase the expression of a pro-apoptosis gene, Bcl2l11. Using chromatin immunoprecipitation we demonstrate
that AGE-modified bovine serum albumin (AGE-BSA) enhances Foxo4 binding to a forkhead binding element in the
promoter of Bcl2lll. AGE-BSA also increases the acetylation of Foxo4. Lysine acetylation of Foxo4 is required for Foxo4
binding and transcription of Bcl2l11 in podocytes treated with AGE-BSA. The expression of a protein deacetylase that targets
Foxo4 for deacetylation, sirtuin (Sirt1), is down regulated in cultured podocytes by AGE-BSA treatment and in glomeruli of
diabetic patients. SIRT1 over expression in cultured murine podocytes prevents AGE-induced apoptosis. Glomeruli isolated
from diabetic db/db mice have increased acetylation of Foxo4, suppressed expression of Sirt1, and increased expression of
Bcl2l11 compared to non-diabetic littermates. Together, our data provide evidence that alteration of Foxo4 acetylation and
down regulation of Sirt1 expression in diabetes promote podocyte apoptosis. Strategies to preserve Sirt1 expression or
reduce Foxo4 acetylation could be used to prevent podocyte loss in diabetes.
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Introduction
Diabetic nephropathy (DN) is the leading cause of renal failure in
thewesternworld.Itisthoughtthathyperglycemiaactivatesmultiple
downstream signaling pathways in the diabetic kidney leading to
extracellular matrix accumulation, endothelium dysfunction, glo-
merular hyperfiltration, oxidant stress, and advanced glycation end
products (AGEs) formation, which all contribute to the development
of DN [1]. Reduction in the density of kidney podocytes occurs early
in the development of DN and correlates with the progression of DN
[2] [3] [4] [5] [6]. Apoptosis of podocytes is a potential cause of
reduction in podocyte number in diabetes. Oxidant stress from
hyperglycemia, angiotensin II, and AGE are known to induce
podocyte apoptosis in diabetes [7], [8], [9].
AGE accumulates in diabetes and reduction of AGE formation
ameliorates the development of DN [10]. We have found
previously that a member of the forkhead box class O (Foxo)
family of transcription factors, Foxo4, is required for AGE-induced
podocyte apoptosis [9]. The Foxo family of transcription factors
(TFs) is involved in the regulation of oxidant stress resistance,
apoptosis, cell cycle inhibition, cellular metabolism, and DNA
damage repair (reviewed in [11]). The activity of Foxo is regulated
by post-translational modifications, including phosphorylation,
ubiquitylation, and acetylation. Change in the acetylation status of
a member of the Foxo family, Foxo3, has been shown to alter the
differential expression of Foxo target genes in a context-specific
manner [12]. In this study, we examined the role of Foxo4
acetylation in podocyte apoptosis in vitro and in vivo. We find that
AGE increases Foxo4 acetylation and suppresses the expression of
the Sirt1 protein deacetylase in kidney podocytes. Acetylated
Foxo4 promotes the expression of a pro-apoptosis gene Bcl2l11
(also known as Bim) and leads podocyte apoptosis.
Methods
Cells and Antibodies
A murine podocyte cell line from Dr. Peter Mundel (Massa-
chusetts General Hospital, Boston, Massachusetts) was cultured as
previously described [9]. The following antibodies were used: a
mouse monoclonal and a rabbit polyclonal Sirt1 antibody
(Millipore, Billerica, MA), a goat polyclonal Foxo4 antibody
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), a rabbit
polyclonal Foxo4 antibody (Cell Signaling Laboratory, Danvers,
MA), a rabbit polyclonal acetyl-lysine antibody (Cell Signaling
Laboratory), a rat monoclonal Bim antibody (Millipore), and a
mouse monoclonal synaptopodin antibody (Fitzgerald Industries,
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endotoxin-free, lyophilized BSA (fraction IV; Sigma, St Louis,
MO) and D-glucose, as described previously [13], [9].
Experimental protocol for diabetes mellitus
Animal studies were performed in accordance with the
guidelines of and approved by the Institutional Animal Care and
Use Committee at the Mount Sinai School of Medicine (Protocol
08-0106-00001-01). Researchers handling animals were trained
and certified according to the guidelines of the American
Association for Laboratory Animals. Diabetic db/db mice on the
C57BLKS background were purchased from Jackson Laboratory,
Bar Harbor, ME and raised in the animal facilities at the Mount
Sinai School of Medicine (New York, NY) according to
standardized specific pathogen-free conditions. Mice were main-
tained on standard mouse chow and allowed free access to tap
water. Four hour fasting serum glucose level was checked every
week from 6 weeks of age. Animals with random serum glucose
levels consistently above 250 mg/dl after 6 weeks of age were
included in the study.
Podocytes with stable over expression of Sirt1
A human Sirt1 cDNA clone purchased from Thermo Scientific
(Huntsville, AL, USA) was PCR amplified and inserted between
BamHI and XhoI of the pDNR-1r vector (Clontech). The Sirt1-
pDNR-1r construct was digested with BamHI and EcoRV then
inserted into a gag-, pol-, and env- deficient lentivector construct,
VVE/BBW (a gift of Dr. G Luca Gusella, Mount Sinai School of
Medicine) to generate the VVE/BBW-Sirt1 lentivector. Lentiviral
particles used to transduce Sirt1 in podocytes were produced in
293T/17 cells (from ATCC; number CRL-11268) by co-
transfection of VVE/BBW-Sirt1 with a packaging and an envelope
plasmid. Podocytes with stable Sirt1 expression (Sirt1) were
selected using blasticidin (8 ug/ml). Podocytes infected with the
backbone lentivector (BB) served as infection controls.
Podocyte with stable over expression of a Foxo4
acetylation mutant
A FLAG-Foxo4 construct (Addgene, Cambridge, MA) was used
as the template to generate a Foxo4 acetylation mutant by PCR-
mediated mutagenesis using QuikChangeH Site-Directed Muta-
genesis Kit (Strategene, La Jolla, CA). Three lysine residues at 186,
189 and 407 were mutated to alanine (Foxo4 KA Mut). The
mutations in Foxo4 KA Mut was confirmed by DNA sequencing.
The mutant was inserted into the VVE/BBW lentivector and
lentiviral particles were generated to tranduce podocytes. Podo-
cytes with stable over expression of Foxo4 KA Mut were selected
using blasticidin.
Podocytes with shRNA-mediated knockdown of Sirt1
Five pKLO.1 replication-incompetent lentiviral vectors con-
taining specific a shRNA targeting Sirt1 [14] were purchased from
Open Biosystems/Thermo Fisher Scientific (Huntsville, AL) and
tested for Sirt1 knockdown in cultured podocytes. Lentivral vector
were co-transfected with a packaging and an envelope vector into
293T cells to generate viral particles. Viral particles were used to
infect conditionally immortalized podocytes cultured at 33uC.
Transduced podocytes were selected using puromycin and
cultured at 37uC for at least 7 days prior to experiments. Of the
four clones of shRNA targeting Sirt1, clone TRCN0000039294
had the most significant knockdown of Sirt1 (.70% knockdown
compared to a scrambled shRNA), which was used in subsequent
experiments.
Western Blotting
Cell lysates were subjected to 8–12% SDS-PAGE prior to
transfer to nitrocellulose membranes as previously described [9].
Densitometric measurements of the band intensities on scanned
images were made using ImageJ [15].
Archival human kidney biopsy samples
Archival human kidney biopsies were collected at Jacobi
Medical Center, Bronx, New York as part of an exempted
protocol (Differential Protein Expression in Nephrotic Diseases),
which was approved by the Einstein Institutional Review Board of
the Albert Einstein College of Medicine of Yeshiva University.
Since all clinical data were de-identified, no consent was required.
Samples included 4 with DN (3 mild DN and 1 nodular DN), 2
with minimal change disease (MCD), and 2 with no apparent
kidney disease on histology (Normal).
Immunostaining of paraffinized kidney sections
Kidney sections from mice were prepared as described [16].
Sirt1 immunostaining was performed using a rabbit polyclonal
Sirt1 antibody. A citrate-based antigen retrieval solution was used.
Endogenous peroxidase was blocked in H2O2. Non-specific
protein binding was blocked with 3% BSA. Sections were
incubated with the Sirt1 antibody (diluted 1:30 in 3% BSA) at
4uC for overnight. After washing, sections were incubated with an
anti-rabbit biotinylated secondary antibody at room temperature,
and then with the avidin–biotin–peroxidase complex (Vectastin
Elite ABC Kit, Vector Laboratories). The reaction products were
developed using the 3, 39-diaminobenzidine substrate from Vector
Laboratory, mounted with a glass coverslip, and photographed
using a Zeiss Axioplan2 microscope with a Q-imaging MP3.3
RTV camera. The number of podocytes with positive Sirt1
staining was counted in 10 glomeruli from each biopsy case.
Podocytes in histologic sections were identified based on
morphology and their location relative to the glomerular basement
and Bowman’s space as previously described [16].
Glomeruli isolation by iron oxide perfusion
Glomeruli were isolated by Fe3O4 perfusion as previously
described [17]. Mice were perfused with Hank’s buffered salt
solution (HBSS) containing 2.5 mg/ml Fe3O4 (Sigma Aldrich, St
Lois MO) and 1% BSA. Kidneys were digested with collagenase A
and DNase I in HBSS at 37uC for 30 min, passed through 100 mm
cell strainers, rinsed with HBSS, and collected using a magnet
(Dynal MPC, Invitrogen, Norway). The purity of the glomeruli
isolate was confirmed by light microscopy and by Western blot for
synaptopodin expression.
Quantification of podocyte apoptosis by flow cytometry
Podocyte apoptosis was quantified by flow cytometry after
annexin V-fluorescein isothiocyanate (FITC) labeling following
manufacturer’s protocol (Annexin V-FITC Apoptosis Detection
Kit I, BD Bioscience, San Jose, CA, USA).
Chromatin immunoprecipiation (ChIP)
ChIP was performed with modifications of an existing protocol
[18]. For each ChIP reaction, 5610
7 podocytes were used. Cells
were serum starved for 16 h prior to treatment with either
100 mg/ml of AGE-BSA or BSA as control and 30 mM of glucose
(HG) or 30 mM of mannitol (Man) as osmotic control. After 2 h of
treatment, cells were crosslinked for 10 min, then quenched with a
glycine buffer. Chromatin was extracted, then sonicated using a
Misonix 3000 Sonicator with a microtip (16 cycles at power 6 with
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performed using a goat anti-Foxo4 antibody linked to tosylacti-
vated magnetic beads (Dynabeads M-450 Tosylactivated, Invitro-
gen). Normal goat IgG tosyl-linked to Dynabeads was used as a
control. Cross-linking was reversed by incubation at 65uC for 8 h
followed by RNAse A and proteinase K digestions. DNA from
immunoprecipitated chromatin was purified using the Qiagen
PCR purification kit (Qiagen, Hilden, Germany). Forkhead
binding elements (FBE) in the promoter of Bcl2l11 were predicted
using a commercial software tool (MatInspector, Genomatix, Ann
Arbor, MI). A pair of oligonucleotide primers flanking a predicted
FBE in the promoter of Bcl2l11 was synthesized. (FBEfor: CTC
TAT TGT GAC GCA CTT ACT A and FBErev: CTT TCC TTC
AGG ACA AAC TTG A). Primer pairs targeting 22241 to
22043 of the translational start site were used to detect nonspecific
immunoprecipitation (NSfor: GGA GTC GGG TCG AGG TCG
CT; NSrev: GGA CGC ACT ACC GGC ACC AC). Amount of
immunoprecipitated DNA was compared by end point PCR with
the following thermoprofile: 94uC63 min, 40 cycles of
94uC615 s, 54uC645 s and 72uC645 s, and followed by
72uC65 min. Quantitative realtime PCR using ChIP DNA
samples as templates and FBEfor and FBErev primer pairs were
performed. Cp values from IgG and Foxo4 antibodies immuno-
precipitated templates were normalized to Cp values from the
corresponding Input DNA templates. Percentage of Input DNA
template was calculated using the formula: percentage of
Input=10062
(Cp of Input2Cp of IgG or Foxo4).
Quantitative real-time PCR
Total RNA was extracted from isolated glomeruli or cultured
immortalized murine podocytes using either RNeasy Mini Kit
(Qiagen) or TRIzol reagent (Invitrogen), respectively. cDNA were
reverse transcribed from total RNA using SuperScript III First-
Strand Synthesis SuperMix (Invitrogen). PCR was performed
using Sybr Green Master Mix (Applied Biosystems, Foster City,
CA) and the Applied Biosystems 7900HT Fast Real-Time PCR
System. The 2
2DDCp method was used for the calculation of
relative gene expression. Primers for realtime PCR were designed
using Primer-Blast (NCBI, Bethesda, MD) to span at least one
intron. Gene expression was normalized to GAPDH as a
housekeeping gene and presented as relative expression compared
to a calibrator sample.
Detection of endogenous Foxo4 acetylation by Western
Blotting
Total protein was extracted from cells or tissues using a lysis
buffer containing inhibitors of Class I, II and III deacetylases
(50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 10 uM trichostatin, 5 mM nicotinamide). Foxo4
was immunoprecipitated using a goat polyclonal anti-Foxo4
antibody. Acetylation of Foxo4 was assessed by Western blotting
using a rabbit anti-acetyl-lysine antibody. Successful immunopre-
cipitation of Foxo4 was confirmed by blotting with a rabbit
polyclonal Foxo4 antibody.
Fluorescence-based Foxo4 acetylation assays
HEK-293 (from ATCC) transfected with the FLAG-Foxo4
construct were serum starved for 18 hrs prior to treatment. Cells
were lysed and FLAG-Foxo4 in the protein lysate was pulled down
using anti-FLAG M2 beads (Sigma, St Louis, MO). Acetylation of
FLAG-Foxo4 was measured using a commercially available kit
(HAT Inhibitor Screening Assay Kit, Cayman Chemical Compa-
ny, Ann Arbor, MI) with some modifications to the protocol: To
determine the relative amount of acetylated lysine residues,
immunoprecipiated Flag-Foxo4 were incubated with acetyl CoA
and an acetylase (P300/CBP-associated factor) for 5 min at room
temperature. The amount of free CoA was determined using 7-
diethylamino-3-(49-maleimidylphenyl)-4-methyl-coumarin (CPM),
which conjugates with free CoA. The amount of CoA-modified
CPM was measured using a plate reader (excitation wavelength of
320 nM and emission wavelength of 450 nm). The relative
fluorescent unit (RFU) measured is indirectly proportional to the
acetylation of FLAG-Foxo4. Relative Foxo4 acetylation at a given
time point is calculated using the following formula: RFUtime 0/
RFUtime x.
Activated Caspase 3 assay
A commercially available ELISA (R&D Systems, Minneapolis
MN) for active caspase 3 (Quantikine) was used to assess apoptosis.
Podocytes (1610
5 cells/condition) transduced and selected for
stable expression of shRNAs targeting either Sirt1 or scrambled
sequence were cultured on type I collagen-coated tissue culture
plates for 7 days prior treatment with either 30 mM of mannitol or
D-glucose for 16 h in serum free medium. For each experimental
condition, active caspase 3 level was measured in duplicates.
Results were normalized to cells transduced with the scrambled
shRNA and treated with mannitol.
Sirt1 expression analysis by cDNA arrays
Data were generated in the context of the European Renal
cDNA Bank–Kro ¨ner-Fresenius Biopsy bank (ERCB-KFB; see
Acknowledgment for participating centers). Human renal biopsy
specimens were obtained after written consent and approval of the
ethics committee and in the frame of the ERCB approved by the
specialized subcommittee for internal medicine of the Cantonal
Ethics Committee of Zurich (Kantonale Ethikkommission Zu ¨rich).
The methods of microdissection and microarray experiments have
been published for glomeruli and tubulointerstitium previously
[19], [20]. The array data were analyzed using ChipInspector
(Genomatix, Munich, Germany), a probe sequence-specific
analysis software for microarray data [20]. All microarray data
are MIAME compliant as detailed on the MGED Society website
http://www.mged.org/Workgroups/MIAME/mia me.html. Mi-
croarray data will be deposited in Gene Expression Omnibus. A
main part of the microarray data is available online at http://
www.nephromine.org.
Statistical analysis
Values are expressed as means 6 S.E.M. Differences between
means were calculated by t-test. In all analyses, the null hypothesis
was rejected at 0.05. Statistical analyses were performed using
either Microsoft Excel or Prism Stat program (GraphPad
Software, Inc., San Diego, CA). For comparison of measurements
from more than 2 groups of samples ANOVA was used.
Results
AGE-BSA induced podocyte apoptosis by promoting
Foxo4-mediated expression of Bcl2l11
We previously found that AGE-BSA increased the expression of
Bcl2l11, which is a Foxo-target gene involved in apoptosis response
[9]. To confirm that Foxo4 binds to the promoter of Bcl2l11 in
AGE-BSA treated podocytes, we examined the binding of
FOXO4 to a predicted Foxo binding element (FBE) upstream of
Bcl2l11 by ChIP. AGE-BSA treatment of cultured podocytes
enhanced Foxo4 binding to the FBE of Bcl2l1l without any
nonspecific binding to a region (22241 to 22043) upstream of the
Foxo4 Acetylation and Podocyte Apoptosis
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1B). Quantitative real time PCR analysis of immunoprecipitated
DNA demonstrated that AGE-BSA significantly increased the
binding of Foxo4 to the FBE of Bcl2l11 compared to BSA
(0.7660.09% vs. 0.0460.2%, p,0.01, Fig. 1C). Nonspecific
binding using normal goat IgG was minimal (Fig. 1A).
AGE-BSA increases Foxo4 acetylation and Bcl2l11
expression
Since oxidant stress is known to increase Foxo3 and Foxo4
acetylation [12], [21], [22] and AGE promotes intracellular
oxidant stress [23], we tested the effects of AGE-BSA (100 mg/ml)
on the acetylation of Foxo4 in murine podocytes. High dose H2O2
(500 mM) was used as a positive control for Foxo4 acetylation.
AGE-BSA treatment increased Foxo4 acetylation, but to a lesser
extent than 500 mMH 2O2 (Fig. 2A). Acetylation of FLAG-Foxo4
in response to AGE-BSA and H2O2 treatments was confirmed in
293 cells using a fluorescence-based acetylation assay (Fig. 2B).
Maximal acetylation occurred between 1 to 2 h after AGE-BSA
stimulation (fold increase in acetylation at 1 h and 2 h are
1.3660.12 and 1.3260.11, p,0.05). H2O2 (500 mM) is a more
potent stimulator of FLAG-Foxo4 acetylation than AGE-BSA at
2 h of treatment (2.8060.22 fold increase in acetylation, p,0.05).
The effect of hyperglycemia on Foxo4 acetylation was also tested.
No significant change in Foxo4 acetylation was observed between
30 mM of D-glucose and 30 mM of mannitol. (Data is not shown).
Acetylation of Foxo4 is required for AGE-mediated
induction of Bcl211 expression
To determine the role of Foxo4 acetylation on Bcl2l11
expression we over expressed a Foxo4 mutant (Foxo4 KA Mut),
which is mutated at three key lysine residues that are known to be
acetylated, and examined the effect of Foxo4 KA Mut on Bcl2l11
expression in response to AGE-BSA treatment. Foxo4 KA Mut
prevented AGE-BSA-induced Bcl2l11 expression as determined
by western blotting and RT PCR (Figure 2C and 2D).
Furthermore, Foxo4 KA Mut binding to the Bcl2l11 promoter
in response to AGE-BSA treatment was reduced in podocytes
confirming that acetylation of Foxo4 is essential for its binding and
transactivation of Bcl2l11 (Figure 2E).
Sirt1 expression is suppressed by AGE-BSA—Sirt1 is a protein
deacetylase that binds and de-acetylates Foxo4 [22]. Since Foxo4
acetylation is enhanced by AGE-BSA, we tested the hypothesis
that AGE-BSA suppresses Sirt1 to promote the accumulation of
acetylated Foxo4. Sirt1 mRNA and protein levels were quantified
by RT PCR and Western blotting, respectively, in podocytes
treated with AGE-BSA. AGE-BSA suppressed Sirt1 mRNA
expression significantly at 50 and 100 mg/ml (Fig. 3A). Down
Figure 1. Binding of Foxo4 to the Bcl2l11 promoter. Conditionally immortalized podocytes were treated with either AGE-BSA (100 mg/ml) or BSA
(100 mg/ml) as control and 30 mM of hyperglycemia (HG) or 30 mM of mannitol (Man) as osmotic control for 2 h. Binding of Foxo4 to a predicted forkhead
binding elementer (FBE) in the promoter region of Bcl2l11 was characterized by chromatin immunoprecipiation (ChIP) using either an anti-Foxo4 antibody
(Foxo4) or normal goal IgG (IgG). (A) Binding was assessed using primers flanking FBE (FBEfor and FBErev) and immunoprecipitated DNA samples as PCR
templates.(B)Primersflankingaregion22241 to22043 upstream of the translational start sitewere used in a PCR reaction with Foxo4 immunoprecipitated
DNA as templates to assess non-specific immunoprecipitation. Representative images of products of endpoint PCR resolved on agarose gels are shown. (C)
Data of quantitative realtime PCR of ChIP DNA using primers flanking the FBE. Results from 3 independent sets of ChIPs. * p,0.05.
doi:10.1371/journal.pone.0023566.g001
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confirmed by Western blotting (Fig. 3B).
Sirt1 expression is reduced in glomeruli of patients with
diabetic nephropathy
Since the level of AGE is elevated in the serum of patient with
diabetes and Sirt1 expression in cultured podocytes is suppressed
by AGE, we examined the expression of Sirt1 in the kidneys of
patients with diabetes. Sirt1 immunostaining of archival kidney
biopsy sections from patients with Normal, MCD, DN (mild DN
and nodular DN) revealed that Sirt1 expression localizes to the
nuclei of both tubular and glomerular cells (Fig. 4). In the
glomeruli, Sirt1 antibody labeled cells near the periphery of the
glomeruli, which are thought to be podocytes (Fig. 4C and 4F,
arrows). The intensity of Sirt1 staining in glomerular cells is
reduced in kidney sections from patients with mild DN compared
to those from MCD and Normal and further reduced in sections
from patients with nodular DN (Fig. 4D to 4I). Sirt1 staining in the
tubules did not appear to be different in patients with MCD and
DN. The estimated average of Sirt1-positive podocytes per
glomeruli in Normal 9.061.1, in MCD is 8.060.25, in DN
(mild+nodular) DN is 2.760.37. A more quantitative assessment of
the expression of Sirt1 in patients with DN was made by querying
the ERCB Consortium for Sirt1 mRNA expression in microdis-
sected glomeruli from an European cohort of diabetic patients
[24]. We compared mRNA levels of Sirt1 (EnTrez Gene 23411;
Representative public ID: NM_012238) in patients with DN
compared to those from living donors of kidney transplantation
(LD) in two independent microarray experiments (DN: n=7 each;
LD: n=4 and 18, respectively). The expression of Sirt1 in patients
with DN from two different sets of experiments was significantly
reduced by 36% and 27%, respectively. There was no statistical
difference in the expression of Sirt1 in the tubulointerstitial
compartment, which is consistent with our observation from Sirt1
immunostaining of kidney biopsy sections.
Sirt1 over expression protects against AGE-BSA-induced
podocyte apoptosis
To determine the role of Sirt1 on AGE-BSA-induced podocyte
apoptosis we over expressed Sirt1 by lentiviral transduction of
Figure 2. Acetylation of Foxo4 is required for AGE-BSA-induced Bcl2l11 acetylation. (A) Acetylation of endogenous Foxo4 in cultured
podocytes treated with 500 mMo fH 2O2, 100 mg/ml of AGE-BSA or 100 mg/ml of BSA for 2 h was assessed by gel electrophoresis of
immunoprecipitating Foxo4, followed by immunoblotted with an anti-acetyl-lysine antibody to detect acetylated Foxo4. Immunoblotting with an
anti-Foxo4 antibody confirms the immunoprecipitation of Foxo4. (B) H2O2- and AGE-BSA-induced acetylation of a FLAG-Foxo4 fusion protein was
confirmed using a fluorescence-based in vitro acetylation assay. 293 cells transfected with a FLAG-Foxo4 fusion construct and serum starved for 16–
18 hrs were treated with either H2O2 (500 mM) or AGE-BSA (50 mg/ml) at 0, 0.5, 1, 2, 4, or 16 hr. (Relative Foxo4 acetylation with AGE-BSA at 1 h is
1.3660.12 and at 2 h is 1.3260.11, *p,0.05, n=4; with 500 mMo fH 2O2 at 2 hr is 2.8060.22 *p,0.05, n=3). The expression of Bcl2l11 in podocytes
with stable over expression of the Foxo4 KA mutant (Foxo4 KA Mut) was compared to control podocytes (BB) after AGE-BSA (100 mg/ml) treatment
for either 24 h (in RT PCR experiments) or 72 h (for Western Blotting experiments). Foxo4 KA Mut over expression abrogated AGE-BSA induced
Bcl2l11 expression as characterized by Western blotting (C) and RT PCR (D). Binding of Foxo4 to the FBE in the Bcl2l11 promoter was reduced in
podocytes with Foxo4 KA Mut over expression as characterized by ChIP of Foxo4 followed by RTPCR using primers flanking FBE (FBEfor and FBErev).
doi:10.1371/journal.pone.0023566.g002
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was confirmed by Western blotting (Fig. 5A). Infection and
selection of stably transduced podocytes were repeated several
times and these cells were used in subsequent experiments. Sirt1
and BB podocytes were exposed to AGE-BSA at either 50 mg/ml
or 100 mg/ml or to BSA at 50 mg/ml as control. Percentage of
apoptotic cells was quantified by flow cytometry after annexin V
FITC labeling. Podocytes with Sirt1 over-expression were
protected from AGE-BSA-induced apoptosis (Fig. 5B). The
percentage of annexin V-FITC positive cells was significantly
higher in BB podocytes exposed to AGE-BSA than Sirt1
podocytes: 7.660.27% vs. 3.860.28% for AGE-BSA 50 mg/ml
and 11.860.75% vs. 5.460.37% for AGE-BSA 100 mg/ml
(Fig. 5B).
Figure 3. Levels of Sirt1 mRNA and protein. A: Total mRNA extracted from podocytes treated with AGE-BSA (10 mg/ml, 50 mg/ml, and 100 mg/
ml) or BSA (100 mg/ml) for 4 h was used to quantify the Sirt1 mRNA level by realtime PCR. Sirt1 expression was significantly reduced with 50 mg/ml
and 100 mg/ml of AGE-BSA compared to 100 mg/ml of BSA. (n=3, * p,0.05) B: Sirt1 is reduced by AGE-BSA (50 and 100 mg/ml) compared to BSA (50
and 100 mg/ml) treatment as assessed by Western blotting. A representative blot is shown here.
doi:10.1371/journal.pone.0023566.g003
Figure 4. Sirt1 immunostaining. Archival renal biopsy samples from patients with no apparent renal disease (normal), minimal change disease
(MCD), mild diabetic nephropathy (mild DN) and nodular DN were used for Sirt1 immunostaining. Representative staining are shown for Normal (A, B,
C) minimal change disease (D, E, and F), mild DN (G and H) and nodular DN (I). Normal rabbit IgG labeling of MCD (J) displayed minimal nonspecific
staining. A higher magnification view (6006) of cells near the periphery of a glomerulus shows the nuclear pattern of Sirt1 staining (arrows in C and
F).
doi:10.1371/journal.pone.0023566.g004
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To assess the role of Sirt1 on hyperglycemia-induced podocyte
apoptosis, we transduced podocytes with either a scrambled or a
Sirt1-targeting shRNA. Sirt1 knockdown was confirmed by
western blotting. Apoptosis was assessed by ELISA measurement
of active caspase 3 in podocytes transduced with either scrambled
or Sirt1-targeting shRNA. Transduced podocytes were treated
with either 30 mM mannitol (MAN) or D-glucose (HG). HG
treatment without Sirt1 knockdown did not significantly increase
active caspase 3 (Fig. 5C). HG treatment, as compared to MAN
treatment, of podocyes with Sirt1 knocked down caused more
significant increase in activated caspase 3 (1.8560.05 vs.
1.3660.09 **p,0.05 for both). Of note, Sirt1 knockdown in
podocytes increased active caspase 3 regardless of treatment
conditions (1.3660.09 vs 0.9860.02 in MAN and 1.8560.05 vs
0.8860.11 in HG. *p,0.05).
Sirt1 expression is reduced, Bcl2l11 expression is
increased, and Foxo4 acetylation is increased in diabetic
db/db mice
Since AGE enhances Foxo4 acetylation in cultured podocytes
and the diabetic milieu is characterized by increased AGE
accumulation, we examined the acetylation of Foxo4 in isolated
glomeruli from diabetic animals. Glomeruli from diabetic db/db
mice and non-diabetic db/m mice on the C57BLKS background
between 7 to 8 weeks of age were isolated by Fe3O4 perfusion. We
had chosen to examine Foxo4 acetylation in the glomerular
isolates from mice between 7 to 8 weeks of age because podocyte
apoptosis in db/db mice has been previously reported to peak at
approximately 8 weeks of age and then declines thereafter [7].
Foxo4 acetylation was detected by immunoblotting for acetylated
lysine in anti-Foxo4 antibody immunoprecipitated glomerular
protein lysates. Foxo4 acetylation is significantly higher in db/db
compared to db/m mice (Fig. 6A and 6B). The expression of Sirt1
is reduced and of Bcl2l11 is increased in isolated glomeruli of db/db
mice compared to their non-diabetic db/m littermates that are
between 11 to 12 weeks of age (Fig. 6C and 6D).
Discussion
Protein lysine acetylation of histones is a key posttranslational
modification that affects chromatin structure and contributes to
the transcriptional regulation of gene expression. Acetylation of
other nuclear transcriptional regulators, such as general transcrip-
tion factors and site-specific DNA binding factors, has also been
shown to regulate protein-DNA and protein-protein interactions,
thereby regulating gene transcription [25]. Although several lines
of evidence indirectly support the link between histone and
transcription factor acetylation in the pathogenesis of diabetes
[26], the role of transcription factor acetylation on the pathogen-
esis of kidney disease in diabetes has never been established. Our
Figure 5. Sirt1 overexpression and knockdown on podocyte apoptosis. The expression of Sirt1 in murine podocyte without infection (no
infection), infected with the empty lentivirus VVE/BBW (BB), or infected with the VVE/BBW-Sirt1 lentivirus with stable overexpression of Sirt1 (Sirt1)
was confirmed by Western blotting (A). Apoptosis of BB (%) and SIRT (&) podocytes treated with BSA (50 mg/ml) or AGE-BSA (50 and 100 mg/ml) for
16 h were quantified by flow cytometry after annexin-V-FITC labeling (B). *p,0.05, n=3. Murine podocytes tranduced with either a scrambled shRNA
or Sirt1-targeting shRNA were treated with either 30 mM of mannitol (MAN) or glucose (HG). Knockdown of Sirt1 expression was confirmed by
Western blotting (C). Fold change in active caspase compared to scrambled shRNA podocytes treated with MAN is shown. *p,0.05, n=3.
doi:10.1371/journal.pone.0023566.g005
Foxo4 Acetylation and Podocyte Apoptosis
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23566results provide the first direct evidence that an alteration in the
acetylation of a transcription factor (Foxo4) in the podocyte
promotes the transcription of a pro-apoptotic gene, Bcl2l11 and
contributes to podocyte loss, which is considered a key mechanism
of diabetic nephropathy.
Acetylation of nuclear transcription regulators has an impor-
tant role in diabetic kidney disease. In addition to Foxo, several
key transcription factors that are known to play a role in podocyte
apoptosis and activated in diabetic nephropathy (i.e. p53 [27],
[28], TGFb/SMAD [29], [30], and Jak/Stat [31]) are regulated
by acetylation and targeted by Sirt1 for deacetylation. Even
though our study suggests that Sirt1 expression and Foxo4
acetylation is altered in diabetes, we have not excluded the
possibility that other targets of Sirt1 might also play a role in
podocyte apoptosis. For instance, Sirt1 has been shown to de-
acetylate p53 in cultured murine kidney mesangial cells and
attenuate oxidative stress-induced apoptosis [32]. In fact, there is
much similarity shared by p53 and Foxo’s with regards to
regulation by post-translational modification (acetylation and
phosphorylation), effects on cell cycle regulation and apoptosis,
and deacetylation by Sirt1 [33]. Furthermore, there is significant
cross talk between Foxo and p53 [33] and other transcription
factors [34]. Transcription factors that are targeted by Sirt1 and
also play a significant role in the pathophysiology of kidney
disease include Smad7 [35], HIF-2a [36], and Stat3 [37]. The
role of Sirt1-mediated deacetylation of p53, Smad7, HIF-2a and
Stat3 in kidney diseases deserves further investigation in the
future.
Although much is known of histone acetyltransferases (HAT)-
mediated change in the acetylation status of nuclear protein, the
role of protein deacetylases is less well characterized. In this study,
we found that the increase in Foxo4 acetylation is linked to a
reduction in the expression of the Sirt1 protein deacetylase. Sirt1 is
known to be involved in cellular resistance to metabolic, oxidative
and hypoxic stress, DNA damage repair, gene transcription,
apoptosis and beneficial effects of caloric restriction. Hao and
Hasse recently reviewed the relevance of SIRT-dependent
pathways on renal physiology and kidney diseases [38]. Sirt1
expression is increased in conditions where there is a reduction of
energy/nutrient (i.e. starvation, caloric restriction) or acute
oxidative stress. We suspect that accumulation of AGE in the
diabetic milieu contributes to the suppression of Sirt1 expression.
However, the exact mechanism of AGE-mediated downregulation
of Sirt1 remains to be identified. The regulation of Sirt1 expression
occurs at both the transcriptional and translational levels: de-
repression of Sirt1 transcription by a hypermethylated-in-
cancer1:C-terminal binding protein repressor complex occurs in
response to oxidant stress [39], phosphorylation of a mRNA
binding protein, HuR, reduces the stability of Sirt1 mRNA [40],
and p53-induced expression of miR34a represses Sirt1 expression
[41]. Since AGEs promote the generation of reactive oxygen
species by activation of NADPH oxidase [42] and p53 activation is
Figure 6. Acetylation of Foxo4 and expression of Sirt1 and Bcl2l11 in isolated glomeruli of db/db and db/m mice. A representative
Western blot of glomerular protein lysates from db/db and db/m mice at 7–8weeks of age were immunoprecipitated with an anti-Foxo4 antibody and
immunoblotted with an anti-acetyl-lysine antibody (A). Immunoblotting for total Foxo4 was used to normalize for sample loading and IP efficiency.
The ratio of band density for acetyl-lysine Foxo4 and total Foxo4 (acetylated/total Foxo4) is presented as relative Foxo4 acetylation (B). Relative band
intensity is significantly higher in db/db than db/m (1.81160.143 vs 1.12360.04, n=4 per group, p,0.05). Glomeruli were isolated from diabetic db/db
and non-diabetic db/m mice at 11–12 weeks of age. mRNA expression of Sirt1 (C) and Bcl2l11 (D) were quantified by real time PCR. Data is presented
as fold change in gene expression relative to db/m.( n=7indb/m group; n=5 in db/db group). *p,0.05.
doi:10.1371/journal.pone.0023566.g006
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downregulation of Sirt1 likely occurs through an oxidant-
dependent mechanism. Although it has been shown previously
that an increase in Sirt1 expression and the interaction of Foxo
and Sirt1 in response to oxidative stress is thought to ‘‘tip the
balance towards cell survival’’ by shifting the expression of Foxo
target genes from apoptosis response to oxidative stress resistance
[44], this salutary effect of Sirt1 on cell survival appears to be
lacking in the diabetic milieu where the podocytes are known to be
apoptosis prone and oxidatively stressed.
Post-transcriptional modifications are important regulators of
Foxo’s transcriptional activity. We have focused on the acetylation
of Foxo4 in the present study since it is known that Sirt1 de-
acetylates Foxos and protects cells from oxidant stress and
apoptosis [12]. We previously shown that AGE reduced the
phosphorylation and increased the nuclear localization of Foxo4 in
cultured podocytes [9].
We had previously speculated that AGE-mediated down
regulation of Sirt1 would promote the acetylation of Foxo and
negate Foxo-mediated the protection against oxidant stress and
apoptosis. Although we observed that the expression of Bcl2l11 is
increased by AGE [9] and the expression of a Foxo-target gene
involved in oxidant stress response—catalase—is suppressed by
AGE, we have not been able to demonstrate a significant change
in the Foxo4 binding to the catalase promoter in response to AGE
treatment (unpublished data). We suspect that AGE-mediated
suppression of catalase is likely mediated through other members
of the Foxo family or other transcription factors.
We also found that hyperglycemia induces activation of caspase
3, however, only when Sirt1 expression is reduced. This suggests
that hyperglycemia by itself is probably not enough to induce
podocyte apoptosis. . However, when Sirt1 expression is reduced
by shRNA, HG caused a significant increased in activated caspase
3 (Fig. 5c). These observations suggest that high glucose could
increase podocyte apoptosis when Sirt1 is suppressed by excess of
AGE. This scenario of hyperglycemia and SIRT1 suppression
likely occurs in the diabetic milieu where prolong hyperglycemia
leads to AGE formation, and AGE reduces SIRT1 expression. The
relatively short treatment duration with high glucose in our
experiment could explain the lack of caspase 3 activation.
The importance of the Sirt1-Foxo4-Bcl2l11 pathway we
described here is consistent with the findings of Kume et al, where
they identified a role for Sirt1 in aging-related nephropathy
affecting the renal cortex [45]. Although we were unable to detect
a significant change in Sirt1 in the tubulointerstitial compartment
of DN, others have reported that the expression of another
member of the sirtuin family, Sirt3 is suppressed in cultured renal
tubular epithelial cells by angiotensin II, a key mediator of the
pathophysiology of diabetic renal disease [46].
Efforts to increase Sirt1 activity by resveratrol treatment [47] or
to increase Sirt1 expression in transgenic mice by knockin [48] or
over expression of a bacterial artificial chromosome containing a
Sirt1 transgene [49] have been shown to improve glycemic
response in murine models of diabetes mellitus. However, in order
to further define the role of Sirt1 on podocyte apoptosis in DN and
avoid potential confounding effects from improved glycemic
control in these Sirt1 over expression models, studies that examine
transgenic animals with podocyte-specific Sirt1 over expression
and diabetes will need to be carried out.
We demonstrated in this study that alteration in the acetylation
status of a transcription factor, Foxo4, is linked to a reduction in
the expression of Sirt1 and contributes to the development of
podocyte loss in diabetes. These findings highlight the importance
of acetylation of nuclear factors in the regulation of gene
expression in an important disease process. A recent study has
shown that protein lysine acetylation is not only limited to nuclear
transcription regulators, but also cellular enzymes that catalyze
intermediate metabolism and plays a major role in metabolic
regulation [50]. The reduction of Sirt1 and associated change in
the status of lysine acetylation could have broad effects ranging
from gene expression to enzymatic activity. Pharmacologic
intervention to normalize Sirt1 expression or prevent acetylation
of Foxo4 should be explored as potential approaches to improve
the outcome of diabetic kidney disease.
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